• Home
  • NEW DAY MEDICINE
  • 2 (64) 2024
  • 38 -2 (64) 2024 - Khusanbaev Kh.Sh., Yusupov A.F., Abdullaeva S.I. - MODERN VIEW OF TREATMENT OF DIABETIC RETINOPATHY AND IT’S COMPLICATIONS

38 -2 (64) 2024 - Khusanbaev Kh.Sh., Yusupov A.F., Abdullaeva S.I. - MODERN VIEW OF TREATMENT OF DIABETIC RETINOPATHY AND IT’S COMPLICATIONS

MODERN VIEW OF TREATMENT OF DIABETIC RETINOPATHY AND IT’S COMPLICATIONS

Khusanbaev Kh.Sh. Republican Specialized Scientific and Practical Center for Eye Microsurgery

Yusupov A.F. Republican Specialized Scientific and Practical Center for Eye Microsurgery

Abdullaeva S.I. Republican Specialized Scientific and Practical Center for Eye Microsurgery

Resume

The paper provides an overview of modern methods of diagnosis and treatment of diabetic retinopathy and its complications. The advantages and disadvantages of individual treatment methods are listed. Indications and contraindications for specific types of treatment for diabetic retinopathy are described. Particular attention is paid to the surgical method of treatment, listing preoperative predictors of high or low functional and anatomical success. Brief summaries of each treatment method are provided.

Keywords: Diabetic retinopathy, vitrectomy, laser

First page

252

Last page

256

For citation: Khusanbaev Kh.Sh., Yusupov A.F., Abdullaeva S.I. MODERN VIEW OF TREATMENT OF DIABETIC RETINOPATHY AND IT’S COMPLICATIONS//New Day in Medicine 2(64)2024 252-256 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Berk Ergun S, Toklu Y, Cakmak HB, Raza S, Simsek S. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage. // Semin Ophthalmol. 2015;30:177-80.
  2. Brourman ND, Blumenkranz MS, Cox MS, Trese MT. Silicone oil for the treatment of severe proliferative diabetic retinopathy. // Ophthalmology. 1989;96:759-64.
  3. Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. // J Diabetes Complications. 2007;21:306-14.
  4. Charles S. Vitreous Microsurgery. Baltimore: Williams and Wilkins; 2002;107-20.
  5. Colin TS, Kiong NW, Wong HK, Yang FP. New insights into diabetic retinopathy-risk factors for prevalence, incidence and progression in Asians. // Annals of the Academy of Medicine Singapore 2012;41(9 Suppl 1): S111.
  6. Dooley I, Laviers H, Papavasileiou E, Mckechnie C, Zambarakji H. Spectral domain ocular coherence tomography findings pre- and post vitrectomy with fibrovascular membrane delamination for proliferative diabetic retinopathy. // Eye (Lond) 2016; 30:34-9.
  7. Eliott D, Lee MS, Abrams GW. Proliferative diabetic retinopathy: Principles and techniques of surgical treatment. In: Ryan SJ, editor. Retina. 4th ed. Amsterdam, The Netherlands: Elsevier Inc; 2006;2413-49.
  8. Fong DS, Aiello AP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004; 27:2540-53.
  9. Gonvers M. Temporary silicone oil tamponade in the treatment of complicated diabetic retinal detachments. // Graefes Arch Clin Exp Ophthalmol. 1990;228:415-22.
  10. Gross JG, Glassman AR, Liu D, Diabetic Retinopathy Clinical Research Network, et al. Diabetic retinopathy clinical research network. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. // JAMA Ophthalmol. 2018;136(10):1138-1148.
  11. Lakhanpal RR, Humayun MS, de Juan E, Jr, Lim JI, Chong LP, Chang TS. Outcomes of 140 consecutive cases of 25-gauge transconjunctival surgery for posterior segment disease. // Ophthalmology. 2005;112:817-24.
  12. Lucke KH, Foerster MH, Laqua H. Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments. // Am J Ophthalmol. 1987;104:624-33.
  13. Mason JO, 3rd, Colagross CT, Haleman T, Fuller JJ, White MF, Feist RM, et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. // Am J Ophthalmol. 2005; 140:231-5.
  14. Mu Eliott D. Vitreoretinal Attachments in Proliferative Diabetic Retinopathy: Effect on Outcome. Vail Vitrectomy Meeting Vail, CO. 2004
  15. Nakazawa M, Kimizuka Y, Watabe T, Kato K, Watanabe H, Yamanobe S, et al. Visual outcome after vitrectomy for diabetic retinopathy. A five-year follow-up. // Acta Ophthalmol (Copenh) 1993; 71:219-23.
  16. Porta M., Kohner E. Screening for diabetic retinopathy in Europe // Diabetic Med. – 1991;8(3):197-198.
  17. Sullu Y, Hamidova R, Beden U, Yakupov K, Canbaz S, Danaci M, et al. Effects of pars plana vitrectomy on retrobulbar haemodynamics in diabetic retinopathy. // Clin Exp Ophthalmol. 2005; 33:246-51.
  18. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction-rhegmatogenous retinal detachment. // Arch Ophthalmol. 1987; 105:503-7.
  19. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic retinopathy vitrectomy study (DRVS) report #1. // Ophthalmology. 1985; 92:492-502.

    file

    download